Synergy Pharmaceuticals Inc fka SGYPQ

[Snackman]

3 Little-Known Pharmaceutical Companies to Put on Your Radar

A team of contributors shares their picks for underappreciated pharmas that deserve more attention.
Cory Renauer, Keith Speights, and Brian Feroldi
(TMFang4apples)

Jan 11, 2017 at 3:42PM

Over the past year, the best-performing drugmaker stocks all have had one thing in common: They received very little attention before providing patient investors windfall gains. Being considered insignificant in itself isn't a great reason to scoop up shares of Teligent (NASDAQ:TLGT), Synergy Pharmaceuticals (NASDAQ:SGYP), or Portola Pharmaceuticals (NASDAQ:PTLA), but these three Motley Fool contributors wanted to share some reasons these underappreciated companies belong on your radar.

2. Synergy Pharmaceuticals: Great momentum
Keith Speights (Synergy Pharmaceuticals): Synergy Pharmaceuticals is on a roll. The stock is up nearly 65% in the past six months. Synergy's experimental gastrointestinal drug, plecanatide, is behind the tremendous momentum.
In December, Synergy announced results from two late-stage clinical studies for plecanatide. Both studies evaluated the drug in treating irritable bowel syndrome with constipation (IBS-C). Synergy expects to submit for regulatory approval in the first quarter of 2017.

The U.S. Food and Drug Administration is currently reviewing Synergy's new drug application for plecanatide in treating chronic idiopathic constipation (CIC). The agency is expected to make its decision by Jan. 29.

While anything can happen with the regulatory process, I think Synergy's chances of approval look pretty good. If approved, plecanatide should have a sizable market -- around 14% of people in North America suffer from CIC. Around 4% to 5% of American adults have IBS-C.

http://www.fool.com/investing/2017/01/11/3-little-known-pharmaceutical-companies-to-put-on.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2